GSBR-1290 is under clinical development by Structure Therapeutics and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GSBR-1290’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GSBR-1290 overview
GSBR-1290 is under development for the treatment of type 2 diabetes and obesity. It is administered through oral route as capsules or tablets. The therapeutic candidate acts as glucagon-like peptide-1 (GLP1) receptor agonist. It is developed based on the Schrodinger artificial intelligence (AI) technology.
See Also:
Structure Therapeutics overview
Structure Therapeutics is a health tech company that provides life-changing medicines for patients using advanced computational and structure-based technology. Structure Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of GSBR-1290’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
